Related Experiment Video
Updated: Jul 10, 2026

Evaluation of Caspase Activation to Assess Innate Immune Cell Death
Published on: January 20, 2023
PI3K/AKT inhibition induces caspase-dependent apoptosis in HTLV-1-transformed cells
Soo-Jin Jeong1, Arindam Dasgupta, Kyung-Jin Jung
1Virus Tumor Biology Section, Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Abstract:
The phosphatidylinositol-3-kinase (PI3K) and AKT (protein kinase B) signaling pathways play an important role in regulating cell cycle progression and cell survival. In previous studies, we demonstrated that AKT is activated in HTLV-1-transformed cells and that Tax activation of AKT is linked to p53 inhibition and cell survival. In the present study, we extend these observations to identify regulatory pathways affected by AKT in HTLV-1-transformed cells. We demonstrate that inhibition of AKT reduces the level of phosphorylated Bad, an important member of the pro-apoptotic family of proteins. Consistent with the decrease of phosphorylated Bad, cytochrome c is released from the mitochondria and caspase-9 is activated. Pretreatment of the cells with caspase-9 specific inhibitor z-LEHD-FMK or pan caspase inhibitor Ac-DEVD-CHO prevented LY294002-induced apoptosis. Of interest, p53 siRNA prevents LY294002-induced apoptosis in HTLV-1-transformed cells, suggesting that p53 reactivation is linked to apoptosis. In conclusion, the AKT pathway is involved in targeting multiple proteins which regulate caspase- and p53-dependent apoptosis in HTLV-1-transformed cells. Since AKT inhibitors simultaneously inhibit NF-kappaB and activate p53, these drugs should be promising candidates for HTLV-1-associated cancer therapy.
Insights
The AKT pathway regulates cell survival in HTLV-1-transformed cells by inhibiting apoptosis. AKT inhibition triggers apoptosis via the caspase and p53 pathways, suggesting AKT inhibitors are promising for cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- The phosphatidylinositol-3-kinase (PI3K)/AKT signaling pathway is crucial for cell cycle regulation and survival.
- AKT is activated in Human T-lymphotropic virus type 1 (HTLV-1)-transformed cells, contributing to cell survival through p53 inhibition.
Purpose of the Study:
- To investigate the regulatory pathways influenced by AKT in HTLV-1-transformed cells.
- To determine the role of AKT in apoptosis and its relationship with p53.
Main Methods:
- Utilized AKT inhibition (e.g., LY294002) in HTLV-1-transformed cells.
- Assessed levels of phosphorylated Bad, cytochrome c release, and caspase-9 activation.
- Employed caspase-9 and pan-caspase inhibitors, as well as p53 siRNA.
Main Results:
- AKT inhibition decreased phosphorylated Bad, leading to cytochrome c release and caspase-9 activation.
- Caspase inhibitors and p53 siRNA blocked LY294002-induced apoptosis.
- p53 reactivation was linked to apoptosis induction.
Conclusions:
- The AKT pathway regulates apoptosis in HTLV-1-transformed cells through caspase- and p53-dependent mechanisms.
- AKT inhibitors show therapeutic potential for HTLV-1-associated cancers by inhibiting NF-kappaB and activating p53.
More Related Videos
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
09:15Tyramide Signal Amplification for the Immunofluorescent Staining of ZBP1-Dependent Phosphorylation of RIPK3 and MLKL After HSV-1 Infection in Human Cells
Published on: October 20, 2022
Related Concept Videos
The Intrinsic Apoptotic Pathway
PI3K/mTOR/AKT Signaling Pathway
The JAK-STAT Signaling Pathway
Caspases
The Extrinsic Apoptotic Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...